X

Stay Connected

Sign Up for Updates

We are creating a place where we can share ideas, provide the perspective of America's biopharmaceutical companies and, most importantly, listen to you.

Video: Translating science into new medicines

By Andrew Powaleny  |    December 12, 2016
Researchers and scientists at America’s biopharmaceutical companies and around the globe work every day to translate science into new treatments and cures to allow patients to live longer,...   Read More

Building on the promise of personalized medicine

By Andrew Powaleny  |    November 16, 2016
PhRMA’s member companies are on the leading edge of personalized medicine development– an area that is transforming health care, improving patient outcomes and creating health system efficiencies....   Read More

ICER puts hard-fought progress in non-small cell lung cancer treatment at risk

By Holly Campbell  |    September 1, 2016
Lung cancer is the leading cause of cancer death among men and women in the United States, and each year, tens of thousands of Americans are diagnosed with the most common form, non-small cell...   Read More

ICYMI: NYT explores how immunotherapy is revolutionizing cancer care

By Holly Campbell  |    August 1, 2016
In case you missed it, this past weekend The New York Times published a series exploring the use of immunotherapy to combat cancer. Cell Wars features a primer on these new therapies and patient...   Read More

ICYMI: ICER solicits feedback on its value assessment framework

By Randy Burkholder  |    July 28, 2016
In case you missed it, the Institute for Clinical and Economic Review (ICER) is seeking suggestions to improve its value assessment framework prior to its re-release in 2017. For the past two...   Read More

What they are saying about ICER’s scoping document for non-small cell lung cancer

By Holly Campbell  |    July 11, 2016
The Institute for Clinical and Economic Review (ICER) has set its sights on a new target: life-saving treatments for advanced non-small cell lung cancer (NSCLC). ICER’s latest draft scoping...   Read More

Burden on patients: Access to medicines in health insurance exchange plans

By Allyson Funk  |    June 23, 2016
Access to prescription medicines is critical to help patients manage their chronic conditions and maximize quality of life. Unfortunately, even with insurance coverage, many patients still...   Read More

Science of Hope: Learning from setbacks

By Andrew Powaleny  |    June 20, 2016
America’s biopharmaceutical research companies are committed to developing new treatments and cures that improve health and save patient lives. Jen O’Neil, principal oncology scientist at Merck,...   Read More

New report: Decade of breakthroughs in cancer

By Emma Van Hook  |    June 2, 2016
The pace of science is yielding remarkable innovation for cancer patients as we learn more about the underlying factors driving the spread and growth of cancer. These advances are opening new...   Read More

ICER framework threatens to halt continued progress against multiple myeloma

By Holly Campbell  |    May 26, 2016
Progress in the fight against multiple myeloma, a cancer of the blood and bone marrow, has been nothing short of remarkable. Just a decade ago, patients diagnosed faced a poor prognosis and...   Read More

Search the Catalyst

View Posts by Topic

see all

Subscribe to Email Updates